

European Scholar Journal (ESJ)

Available Online at: https://www.scholarzest.com

Vol. 2 No. 3, March 2021,

ISSN: 2660-5562

QUANTITATIVE DETERMINATION OF THE PREPARATION COBALT-30 AND ITS COMPARISON OF LEUKOPOESSTIMULATING EFFECTIVENESS

Mukhamedova Busora Ibragimovna

Tashkent Pharmaceutical Institute

Berdiyeva Malika Ibodullaevna

Tashkent Institute of Chemical Technology, Associate Professor, Phd berdievamalika55@gmail.com

Ibodulloeva Mavzjuda Ibodulloevna

Candidate, Associate Professor of Chemical Sciences Tashkent State PedagogicalNizami University mibodulloveva69@amail.com

Turakulov Jakhongir Ulugbekovich

jakhongir.turakulov@gmail.com Tashkent Pharmaceutical Institute

Article history:		Abstract:								
Received:	11 th February 2021	Under the influence a drug increase the content of Cobalt-30 stick core								
Accepted:	28 th February 2021	leukocetes. The effect of the drug was compared with lacto flora. Both drugs								
Published:	16 th March 2021	have the same effect, but the performance is better. Cobalt-30 is easily tolerated and has no side effects. The drug can be used in the clinic for the treatment of leukopenia state. The developed methods of mass-spectrometric determination of Cobalt-30 tablets								

Keywords: Cobalt-30, mass-spectrometry, leukocetes, quantitative determination, drug

1.INTRODUCTION.

Now the pharmaceutical market of Uzbekistan is one of dynamically developing sectors of national economy, and the range of antianemic preparations are widely presented. However the analysis of price and assortment policy in the market the antianemic preparations of medicines showed the importance of taking measures to development and deployment into production of domestic substances and dosage forms, and also diversification of a domestic production, by developing assortment versions and introducing import-substituting production is necessary. It is known at the Tashkent pharmaceutical institute there has been conducted purposeful synthesis of medicinal preparations based of coordination compounds of biometals [1-9].

Actual problem of standardization and quality control of medicines based on coordination compounds is developing and introducing those methods that would most fully reflect chemical essence of a complex, namely its chemical structure, valent coordination condition of metal and identity of preparation. Cobalt-30 coordination compound of cobalt with methionine represents fine-crystalline pink color powder with a slight specific smell. The purpose of this research is developing of a technique of quantitative definition of cobalt-30 in tablets by a mass spectrometry method with inductively connected plasma. Unique opportunities of mass spectrometry allow using it for research of fundamental bases of chemistry, pharmacy and creating scientific bases of forecasting, searches and complex using new medicines for applied medicine. Detection limits for the majority of elements make less than 1·10-9 grams, and dynamic range allows defining at the same time concentration of impurity elements and main components of tests. Mass and spectrometer definition is executed by "A technique of performance of measurement of mass fractions in breeds and soils by a nuclear and absorbing method" (No. 290 MVI: 2006) with using ISP - a mass spectrometer of ELAN-6000 of Perkin Elmer firm (USA).

2.EXPERIMENTAL PART.

The quantitative determination of Cobalt-30 is carried out by a complexometric method with an indicator xylenol orange (TU 6-09-1509-78) in an acetate buffer medium according to the following procedure: 4-5 ml of 2 mol / I hydrochloric acid solution, slightly heated until dissolved, add 50 ml of water and heat to boiling. To the resulting solution, add 40-50 ml of acetate buffer mixture (pH 4-6.5), 4-5 drops of xylenol orange indicator and titrate with 0.05 mol/l Trilon B solution from a semi-micro burette until the crimson color turns yellow. 1 ml of 0.05 mol/l Trilon B solution corresponds to 0.01777 g of Cobalt-30.

European Scholar Journal (ESJ)

Statistical processing of the results obtained was carried out in accordance with the requirements of the State Fund XI, no. 1, p. 199 and document Uz T 51-153-2007 (Table 1).

Definition method of cobalt-30 in tablets: about 0,3 g (an exact hinge plate) pounded tablets powder of Cobalt-30 incinerated in a platinum crucible in the muffle furnace at $450-500^{\circ}$ C. The rest was processed by 10 ml of the concentrated hydrochloric acid, dry evaporated, flowed 10 ml 2 M HCl, filtered in a measured flask on 25 ml, a crucible washed out water, washing waters united with a filtrate and brought volume to a tag water. Amount of cobalt found 240,7 nanometers on the resonant line. Characteristic concentration of Cx = 0,15 mkg/ml; detection limit C = 0,01 mkg/ml

Table 1. Results of quantitative determination of Cobalt-30 in tablets

Table 1. Results of quantitative determination of Cobalt-30 in tablets												
Nō	Weight,	Titrant	Found	Average	Content.		S ²		. =	_		
	g	volume,	Co-30 in			χ̄,Γ	10 ⁸	$S_{\overline{X}}$.	$\Delta \overline{X}$	$\overline{\mathrm{E}}$,		
		ml	the	1 tablet,	1 tablet,		10	10 ⁴	10 ³	%		
			sample	g	x, g							
			taken, g									
1	2	3	4	5	6	7	8	9	10	11		
0.015g t	tablets											
010505		2,75	0,04875	0,3036	0,0148	0,0146	3,0	1,0	4,30	2,94		
	1,0000	2,69	0,04776		0,0145							
	1,0044	2,70	0,04797		0,0144							
020505	1,0012	2,84	0,05046	0,2984	0,0153	0,0151	4,0	1,155	4,97	3,29		
	1,0020	2,82	0,05003		0,0149							
	1,0006	2,85	0,05063		0,0151							
030505	1,0034	2,67	0,04747	0,3065	0,0145	0,0145	4,0	1,155	4,97	3,43		
	1,0027	2,71	0,04809		0,0147							
	1,0016	2,63	0,04673		0,0143							
040505	1,0042	2,84	0,05043	0,2987	0,0150	0,0148	4,0	1,155	4,97	3,36		
	1,0056	2,78	0,04915		0,0146							
	1,0038	2,80	0,04974		0,0148							
050505	1,0025	2,93	0,05213	0,3077	0,0160	0,0158	3,0	1,0	4,30	2,72		
	1,0007	2,87	0,05106		0,0157							
	1,0013	2,88	0,05109		0,0156							
0.020g t	tablets											
060505	1,0040	3,44	0,06114	0,3498	0,0213	0,0215	3,0	1,0	4,30	2,0		
	1,0028	3,48	0,06192		0,0216							
	1,0034	3,49	0,06196		0,0215							
070505	1,0025	3,13	0,05555	0,3501	0,0194	0,0194	1,0	0,577	2,481	1,28		
	1,0035	3,14	0,05584		0,0195							
	1,0015	3,11	0,05521		0,0193							
080505	1,0052	3,20	0,05689	0,3534	0,0200	0,0198	4,0	1,154	4,962	2,51		
	1,0060	3,14	0,05579		0,0196							
	1,0048	3,17	0,05630		0,0198							
090505	1,0022	3,31	0,05880	0,3460	0,0203	0,0200	7,0	1,528	6,570	3,28		
	1,0018	3,23	0,05733		0,0198							
	1,0010	3,24	0,05757		0,0199							
100505	1,0017	3,38	0,06004	0,3570	0,0214	0,0212	4,0	1,154	4,962	2,34		
	1,0026	3,35	0,05954		0,0212							
	1,0009	3,31	0,05888		0,0210							

Statistical processing results of quantitative definition of Cobalt-30 in tablets showed that the calculated values of control criterion for identification of gross blunders of Qi don't exceed tabular Q(0,95 value; 3) = 0,94 therefore selection of small volume (n <10) it is uniform, it isn't burdened by a gross blunder and values of X, S2 and S are reliable. The relative standard error of a mass and spectrometer method doesn't exceed 2,5% for the analysis of Cobalt-30tablets.

Developed in Tashkent pharmaceutical institute preparation Cobalt-30 is the haemo stimulating substance which is especially effectively operating on granulocytopoiesis at secondary leukopenia. Prolonged use Cobalt-30 has no negative effect on a gistomorfology of the vital internals. Clinical tests of Cobalt-30 were carried out under the leadership of the prof. Memetov F.B., assistant-professor H.H. Tuydzhanova (RONTS), prof. M .A. Isamukhamedova and candidate of medical sciences of Ya.S. Mamadaliyeva (The institute of improving qualification of physicians) and prof. A.A. Buglanov (SRI of Hematology) in patients with hemopoiesis disturbances which are especially followed by a leucopenia state arising at action of the ionizing radiation and for preventing and treating patients with malignant

European Scholar Journal (ESJ)

tumors. There has been evaluated the efficiency and shipping Cobalt-30 tablets in patients suffering from the secondary leucopenia which arose owing to chemotherapy of malignant new growths.

Cobalt-30 was appointed with 1 tablet 3 times a day before food within 3-4 weeks. Patients in the comparison group were received by Lacto Flore within 30 days. The clinical assessment was carried out on extent by improving of peripheral blood picture (leukocytes quantities) and the general condition of the patient. There have been conducted researches of cardiovascular system and breath conditions (an electrocardiogram, arterial pressure, etc.) and also a number of biochemical analyses. Received results are processed by variation statistics method.

Results of clinical tests showed that from 90 patients the positive haemo stimulating effect is noted at 69 patients (81,2%) and weak effect – at 11 patients (12,9%). Efficiency of Cobalt-30 is studied in comparative aspect with LAKTOFLOR which also renders the haemo stimulating effect at the leykopenia. It is established that effect of cobalt-30 is equivalent to Lacto Flore's action. However Cobalt-30 has more specific effect on leukopoiesis. It is necessary to emphasize that Cobalt-30 generally renders the haemo stimulating effect on granular leukocytes whereas on non granule lymphocyte cells of patients with lymph - proliferative diseases the haemo stimulating effect isn't shown.

3.CONCLUSIONS:

- 1. Developed methods of mass spectrometer definition of cobalt-30 in tablets possess quite high sensitivity and accuracy and can be used for an assessment of preparations on indicators: "Dissolution", "Uniformity of dispensing" and "Quantitative definition".
- 2. Conducted researches showed that tablets effectively stimulate cobalt-30 leukopoes are well tolerated by patients; have no essential impact on cardiovascular, respiratory, nervous and secretory systems of an organism.

REFERENCES:

- A.N.Yunusxodjaev. Sink-defitsitnoe sostoyaniya: vzglyad na problemu/ Meditsinskiy jurnal Uzbekistana, 2008.
 №5. P. 56-58.
- 2. Sadriddinov A.F. Smalyuk N.G., Isamuhamedova M.A., Muxamedova B.I., Klinicheskaya effektivnost kobalta-30 pri lechenii bolnix vtorichnoy leykopeniniy/ X !! Rossiskiy natsionalniy congress "Chelovek i lekarstvo": Tez. Dokl.M; 2005.231 p.
- 3. Smalyuk N. G., Sadriddinov A.F., Tuyjanova X.X., Muxamedova B.I. Opit primeneniya preparata Kobalt-30 v kachestva stimulyatora leykopoeza // Sankt- Peterburgskaya assambleya-2004 "Vrach provizor-patient": Tez/dok. SPb;2004.75 p.
- 4. Farmakopeya. Izd. 11-e. M; Meditsina. 1987. Vip. 205 p.
- 5. Saipova D.T. Retrospektivniy analiz v statsionarniy usloviyax // Materiali nauchno-prakticheskoy konferensii: "Aktualnie voprosi obrazovaniya, nauki i proizvodstva v farmatsii".- Tashkent, 2008.- P.228-229.
- 6. Xavezov I., Salev D., Atomno-absorbtsionniy analiz. Leningrad: Ximiya, 1983. 89-92 p.
- 7. Kozlov V.V., Muxamedova D.V. Analiticheskaya baza Instituta geologii i Geofizika im. X.M. Abdullayeva A.N RUz // Sovremennie analiticheskaya metodi i pribori v geologii i oxrane okrujayushey sredi: Tez. Dokl. Nauchnogo Seminara 12-14 oktyabrya, 1998.- Tashkent, 1998.- P. 10.